TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy
Brief Summary: 1. Determine the "dose-response" relationship between a cash transfer amount and HIV viral suppression at 6 months
2. Identify the most effective cash transfer size to increase the proportion of people living with HIV infection (PLHIV) retained in care and with suppressed viral load (\<1000 copies/ml) after 6 months. (This amount will be further evaluated in a cluster randomized trial in Phase 2).


Options:
A: Arm Label: Full Service Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Full Service | Arm Label: Basic Service Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Service | Arm Label: Usual Services; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Full Service; Assigned to Arm(s): Full Service Treatment | Intervention Type: BEHAVIORAL; Name: Basic Service; Assigned to Arm(s): Basic Service Treatment
B: Arm Label: Comparison Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active Intervention 1; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm 1 | Arm Label: Active Intervention 2; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm 2 | Intervention Type: BEHAVIORAL; Name: Active Arm 1; Assigned to Arm(s): Active Intervention 1 | Intervention Type: BEHAVIORAL; Name: Active Arm 2; Assigned to Arm(s): Active Intervention 2
C: Arm Label: Treatment as Usual (TAU) Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient Navigation (PN) Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigation (PN) Group | Arm Label: Patient Navigator Plus Contingency Management (PN+CM) Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigator Plus Contingency Management (PN+CM) Group | Intervention Type: BEHAVIORAL; Name: Patient Navigation (PN) Group; Assigned to Arm(s): Patient Navigation (PN) Group | Intervention Type: BEHAVIORAL; Name: Patient Navigator Plus Contingency Management (PN+CM) Group; Assigned to Arm(s): Patient Navigator Plus Contingency Management (PN+CM) Group
D: Arm Label: Facebook intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook intervention | Arm Label: Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smokefree.gov | Intervention Type: BEHAVIORAL; Name: Facebook intervention; Assigned to Arm(s): Facebook intervention | Intervention Type: BEHAVIORAL; Name: Smokefree.gov; Assigned to Arm(s): Referral

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy
Brief Summary: 1. Determine the "dose-response" relationship between a cash transfer amount and HIV viral suppression at 6 months
2. Identify the most effective cash transfer size to increase the proportion of people living with HIV infection (PLHIV) retained in care and with suppressed viral load (\<1000 copies/ml) after 6 months. (This amount will be further evaluated in a cluster randomized trial in Phase 2).


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Information Communication Technology Continuum of Care Service | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: Information Communication Technology Continuum of Care Service; Assigned to Arm(s): Intervention arm | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): Control Arm
B: Arm Label: Comparison Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active Intervention 1; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm 1 | Arm Label: Active Intervention 2; Type: EXPERIMENTAL; Interventions: Behavioral: Active Arm 2 | Intervention Type: BEHAVIORAL; Name: Active Arm 1; Assigned to Arm(s): Active Intervention 1 | Intervention Type: BEHAVIORAL; Name: Active Arm 2; Assigned to Arm(s): Active Intervention 2
C: Intervention Type: BEHAVIORAL; Name: Guideline adherence and financial incentive; Assigned to Arm(s): N/A
D: Arm Label: Nutrition PBF; Type: EXPERIMENTAL; Interventions: Other: Nutrition PBF | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nutrition PBF; Assigned to Arm(s): Nutrition PBF

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRCA Founder OutReach (BFOR) Study
Brief Summary: The purpose of this study is to learn how to provide BRCA gene testing to a larger number of people as well as to make testing part of a person's regular medical care.


Options:
A: Arm Label: Incentive schemes 1; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 2; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 3; Type: N/A; Interventions: N/A | Arm Label: Incentive schemes 4; Type: N/A; Interventions: N/A
B: Arm Label: Monetary incentive; Type: EXPERIMENTAL; Interventions: Behavioral: Questionnaire and monetary incentive | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Questionnaire only | Intervention Type: BEHAVIORAL; Name: Questionnaire and monetary incentive; Assigned to Arm(s): Monetary incentive | Intervention Type: BEHAVIORAL; Name: Questionnaire only; Assigned to Arm(s): Control
C: Arm Label: Participants with Ashkenazi ancestry; Type: N/A; Interventions: Other: BFOR Digital Health solution/Web Portal | Intervention Type: OTHER; Name: BFOR Digital Health solution/Web Portal; Assigned to Arm(s): Participants with Ashkenazi ancestry
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of A New Crosslinked Hyaluronan Gel in the Prevention of Postoperative Intrauterine Adhesion After Dilatation and Curettage in Women With Delayed Miscarriage: A Prospective, Randomized, Controlled Trial
Brief Summary: Using American Fertility Society classification of intrauterine adhesions, the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesion formation after dilatation and curettage for delayed miscarriage in women without previous dilatation and curettage was examined.


Options:
A: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: new crosslinked hyaluronan gel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: new crosslinked hyaluronan gel; Assigned to Arm(s): Treatment
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
D: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study
Brief Summary: To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.


Options:
A: Arm Label: Family-Enhanced Non-directive Supportive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Enhanced Non-directive Supportive Therapy | Arm Label: Attachment-Based Family Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment-Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Attachment-Based Family Therapy; Assigned to Arm(s): Attachment-Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Family-Enhanced Non-directive Supportive Therapy; Assigned to Arm(s): Family-Enhanced Non-directive Supportive Therapy
B: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
C: Arm Label: Adjunctive Internet-delivered ERITA; Type: EXPERIMENTAL; Interventions: Behavioral: Emotion regulation individual therapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Emotion regulation individual therapy; Assigned to Arm(s): Adjunctive Internet-delivered ERITA | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
D: Arm Label: ASSIP + TAU goup; Type: EXPERIMENTAL; Interventions: Other: ASSIP | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ASSIP; Assigned to Arm(s): ASSIP + TAU goup

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study
Brief Summary: To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.


Options:
A: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up
B: Arm Label: MEDIA; Type: EXPERIMENTAL; Interventions: Other: MEDIA | Arm Label: CLASSIC; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MEDIA; Assigned to Arm(s): MEDIA
C: Arm Label: Dialectical Behavior Therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Dialectical Behavior Therapy | Arm Label: Dialectical Behavior Therapy placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy | Arm Label: Supportive therapy Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Supportive psychotherapy | Arm Label: Supportive therapy placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive psychotherapy | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Supportive therapy Fluoxetine | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): Dialectical Behavior Therapy Fluoxetine, Dialectical Behavior Therapy placebo | Intervention Type: BEHAVIORAL; Name: Supportive psychotherapy; Assigned to Arm(s): Supportive therapy Fluoxetine, Supportive therapy placebo
D: Arm Label: Adjunctive Internet-delivered ERITA; Type: EXPERIMENTAL; Interventions: Behavioral: Emotion regulation individual therapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Emotion regulation individual therapy; Assigned to Arm(s): Adjunctive Internet-delivered ERITA | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
Brief Summary: Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events


Options:
A: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO
B: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: placebo | Arm Label: Rivaroxaban 5mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Arm Label: rivaroxaban 10mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban 5mg, rivaroxaban 10mg | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Rivaroxaban 5mg, aspirin, rivaroxaban 10mg
C: Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): N/A
D: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
Brief Summary: Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events


Options:
A: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
C: Arm Label: RECO thrombectomy; Type: EXPERIMENTAL; Interventions: Device: RECO flow restoration device | Arm Label: Solitaire FR thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Solitaire FR flow restoration device | Intervention Type: DEVICE; Name: RECO flow restoration device; Assigned to Arm(s): RECO thrombectomy | Intervention Type: DEVICE; Name: Solitaire FR flow restoration device; Assigned to Arm(s): Solitaire FR thrombectomy
D: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
Brief Summary: Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events


Options:
A: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)
B: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
C: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO
D: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack
Brief Summary: Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events


Options:
A: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: TICAGRELOR; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Arm Label: TICAGRELOR PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): TICAGRELOR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TICAGRELOR PLACEBO
C: Arm Label: Monotherapy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel | Arm Label: DAPT group; Type: EXPERIMENTAL; Interventions: Drug: aspirin, Drug: clopidogrel, Drug: cilostazol | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): DAPT group, Monotherapy group | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): DAPT group
D: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Brief Summary: This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult patients with relapsed and refractory B-cell Non-Hodgkin lymphoma.


Options:
A: Arm Label: Human CD19 targeted T Cells Injection; Type: EXPERIMENTAL; Interventions: Drug: Human CD19 targeted T Cells Injection | Intervention Type: DRUG; Name: Human CD19 targeted T Cells Injection; Assigned to Arm(s): Human CD19 targeted T Cells Injection
B: Arm Label: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Arm Label: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Type: EXPERIMENTAL; Interventions: Biological: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg) | Intervention Type: BIOLOGICAL; Name: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg); Assigned to Arm(s): CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
C: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: lymphodepleting chemotherapy, Drug: Bridging Therapy | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: lymphodepleting chemotherapy; Assigned to Arm(s): Tisagenlecleucel | Intervention Type: DRUG; Name: Bridging Therapy; Assigned to Arm(s): Tisagenlecleucel
D: Arm Label: JWCAR029; Type: EXPERIMENTAL; Interventions: Biological: JWCAR029 | Intervention Type: BIOLOGICAL; Name: JWCAR029; Assigned to Arm(s): JWCAR029

Answer: D